An unprecedented treatment for autistic patients in 2020

بحث هذه المدونة الإلكترونية

Powered by Blogger.

إعلان أدسنس

آخر المواضيع

Monday, May 20, 2019

An unprecedented treatment for autistic patients in 2020

A new drug called "balovaptan" has achieved unprecedented positive results in clinical research for the treatment of autism spectrum disorder (ASD) patients.

The drug also received approval from the US Food and Drug Administration (FDA) recently, which increased the enthusiasm of Roche, the Swiss pharmaceutical industry and development, which developed the new drug in the laboratories of the Genentech development and research in the United States, to announce the acceleration of the pace of work to come out New property to market in 2020 at most.

The mechanism of action of the property

Balovaptan, a vasopressin 1a (V1a) antagonist previously known as RG7314, has shown positive potential in improving social interaction and communication in people with ASD, according to the publication of PharmaTimes.

The clinical trial evidence suggests that the V1a receptor antagonist implicitly contributes to the modification and improvement of key social behaviors, such as repetitive behavior, restricted interests and communication problems, which challenge individuals with autism who currently have no drug treatments.

Meanwhile, Sandra Horning, medical director of Roche and head of global product development at the company, said in a statement quoted by Reuters news agency, HE Roche announced that the FDA had granted balovaptan an "unprecedented treatment" rating, expressing the US Commission's belief in the positive results of balovaptan For people with autism around the world.

"Roche is looking forward to working closely with the FDA in order to produce the drug as soon as possible," Hawring said.

Horning's comments follow a recent delay in the production of the drug by the Genentech unit of the California-based research and development arm of pRED in Roche.

According to the site scoop disability, the FDA gives a ranking or label "unprecedented treatment" to accelerate the development of promising drugs that address serious diseases. Under this classification, the FDA provides additional assistance and priority to the drug manufacturer as it develops and manufactures the new drug, to be provided to patients as soon as possible.

Global estimates

WHO estimates that the global prevalence of autism is about 1 in 160 people. In the EU, estimates range from 57-67 for every 10,000 children, while accurate estimates of autism prevalence are not available in developing countries. The available estimates indicate that the prevalence of the disease is among 24 out of every 10,000 children. However, there is no documented documentation of this statistic because of many factors, including the lack of correct diagnosis or the concern of some families to integrate their children in regular schools instead of specialized centers and other factors that are related to the conditions of third world countries.

Types of autism

Autism, also known as a range of autism spectrum disorders or various pervasive developmental disorders, is caused by neurodevelopmental disorder, which results in impaired social interaction, verbal and nonverbal communication, and frequent and repetitive behavioral patterns.

Diagnosis criteria require that symptoms become apparent before the child is 3 years old. Autism affects the process of processing data in the brain by changing how neurons are connected and the points of their collisions; it is not yet understood exactly how this happens.

Autism is one of three disorders under ASD. The second and third disorders are asperger syndrome, the symptoms of delayed cognitive growth and language, and the so-called "pervasive developmental disorder", which is abbreviated to PDD NOS, The prevalence of criteria for the determination of autism or Asperger syndrome.

:see more
What causes autism?

Post a Comment